Overall, these observations (Fig. 6; Supplementary Figs. S2–S5) demonstrated that the changing mutational spectra in RRD-HGG affect the tumor, its microenvironment, and the peripheral immune response, providing a mechanistic rationale for the continued, albeit delayed response to continued anti–PD-1 monotherapy. Here, PDCD1 is linked to neoplasm.